Stock TSHA TAYSHA GENE THERAPIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.39 USD +3.91% Intraday chart for Taysha Gene Therapies, Inc. +5.29% +35.03%
Apr. 09 Piper Sandler Initiates Taysha Gene Therapies at Overweight Rating With $9 Price Target MT
Mar. 21 Chardan Adjusts PT on Taysha Gene Therapies to $7 From $5 as Gene Therapy for Rett Syndrome Shows 'Sustained Benefit', Keeps Buy Rating MT

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,002 448.2 141.1 330.9 447 - -
Enterprise Value (EV) 1 750.9 299.1 91.21 227.5 344.6 303.2 92.35
P/E ratio -7.81 x -2.51 x -0.6 x -1.84 x -5.89 x -5.03 x -6.42 x
Yield - - - - - - -
Capitalization / Revenue - - 56.4 x 21.4 x 48.5 x 87.8 x 8.72 x
EV / Revenue - - 36.5 x 14.7 x 37.4 x 59.6 x 1.8 x
EV / EBITDA -17.5 x -1.73 x -0.73 x -3.2 x -5.11 x -3.34 x 2.67 x
EV / FCF -24.4 x -2.26 x -0.84 x -2.96 x -5.55 x -4.1 x -1.01 x
FCF Yield -4.1% -44.2% -120% -33.8% -18% -24.4% -99.4%
Price to Book 3.99 x 4.7 x 105 x 4.42 x 47.8 x -6.64 x -
Nbr of stocks (in thousands) 37,761 38,474 62,442 186,960 187,018 - -
Reference price 2 26.54 11.65 2.260 1.770 2.390 2.390 2.390
Announcement Date 3/3/21 3/31/22 3/28/23 3/19/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - 2.502 15.45 9.217 5.09 51.25
EBITDA 1 -42.99 -172.8 -124.9 -71.07 -67.48 -90.9 34.54
EBIT 1 -43 -173.3 -162.4 -72.44 -74.63 -91.2 -79.79
Operating Margin - - -6,492.69% -468.83% -809.73% -1,791.62% -155.7%
Earnings before Tax (EBT) 1 -60.01 -174.5 -166 -111.6 -77.86 -94.78 -75.55
Net income 1 -60.01 -174.5 -166 -111.6 -77.86 -92.9 -69.45
Net margin - - -6,635.25% -722.06% -844.81% -1,825.16% -135.52%
EPS 2 -3.400 -4.640 -3.780 -0.9600 -0.4060 -0.4756 -0.3725
Free Cash Flow 1 -30.81 -132.3 -109 -76.89 -62.07 -73.98 -91.77
FCF margin - - -4,356.87% -497.62% -673.48% -1,453.46% -179.09%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 3/3/21 3/31/22 3/28/23 3/19/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - - 2.502 4.706 2.395 4.746 3.604 2.305 2.31 2.295 2.315 3.101
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -50.68 -49.72 -49.27 -32.98 -25.07 -55.12 -16.56 -23.38 -15.63 -16.25 -18.54 -19.19 -19.74 -19.52 -22.4
Operating Margin - - - - - -2,203.04% -351.87% -976.37% -329.41% -450.78% -804.17% -830.67% -859.84% -843.16% -722.28%
Earnings before Tax (EBT) 1 -51.19 -50.39 -50.11 -33.87 -26.31 -55.72 -17.62 -24.6 -117.1 47.74 -19.27 -19.76 -20.18 -20.16 -22.42
Net income 1 -51.19 -50.39 -50.11 -33.87 -26.31 -55.72 -17.62 -24.6 -117.1 47.74 -19.27 -19.76 -20.18 -20.16 -22.42
Net margin - - - - - -2,227.14% -374.46% -1,027.06% -2,467.07% 1,324.67% -835.72% -855.31% -879.16% -870.48% -722.87%
EPS 2 -1.350 -1.320 -1.310 -0.8400 -0.6400 -0.9900 -0.2800 -0.3800 -0.9300 0.9200 -0.1111 -0.1156 -0.1167 -0.1133 -0.1100
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/10/21 3/31/22 5/16/22 8/11/22 11/8/22 3/28/23 5/11/23 8/14/23 11/14/23 3/19/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 251 149 49.9 103 102 144 355
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 -30.8 -132 -109 -76.9 -62.1 -74 -91.8
ROE (net income / shareholders' equity) -47.8% -101% -345% - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 6.650 2.480 0.0200 0.4000 0.0500 -0.3600 -
Cash Flow per Share - - - - - - -
Capex 1 0.08 15.3 20.6 3.87 4.52 3.41 4.95
Capex / Sales - - 824.1% 25.04% 49.08% 67.05% 9.65%
Announcement Date 3/3/21 3/31/22 3/28/23 3/19/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Taysha Gene Therapies, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.39 USD
Average target price
6.833 USD
Spread / Average Target
+185.91%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TAYSHA GENE THERAPIES, INC. Stock Taysha Gene Therapies, Inc.
+35.03% 447M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TSHA Stock
  4. Financials Taysha Gene Therapies, Inc.